Mighty Therapeutics announced the closing of transactions securing up to $150 million in non-dilutive growth and equity capital. The financing is designed to support the company’s commercial and clinical development plans for a new class of medicines targeting mitochondrial dysfunction.
Mighty is a commercial-stage biotechnology company focused on rare and age-related diseases involving mitochondrial dysfunction. The company said the financing strengthens its runway as it advances launch activities, late-stage development programs, and earlier pipeline initiatives.
The financing includes a credit facility of up to $125 million from K2 HealthVentures, an alternative investment firm providing flexible, long-term financing solutions to life sciences and healthcare companies. The facility includes an initial $30 million tranche funded at signing.
Mighty also held an initial closing of its Series B financing, with founding investor Morningside investing $25 million.
The company said its current cash and cash equivalents, together with revenue from sales of its lead commercial product, are expected to support further acceleration of launch activities and ongoing late-stage development work. Mighty’s key development areas include dry age-related macular degeneration and polymerase gamma-related mitochondrial disease.
The financing is also expected to help expedite pipeline initiatives in Parkinson’s disease and long-chain fatty acid disorders. Mighty said its current resources extend the cash runway into 2028, while subsequent drawdowns available under the K2HV facility are expected to extend the runway to projected cash flow positivity in early 2029.
Under the credit facility, the first $30 million term loan was funded upon signing. A second $25 million term loan is expected to be available for drawdown through early 2028, subject to Mighty achieving specified commercial, clinical, and regulatory milestones.
A third $20 million term loan is expected to be available for drawdown through early 2029, subject to specified commercial, clinical, regulatory, and financing milestones. An additional $50 million tranche is available for draw at Mighty’s option, subject to K2HV’s discretion.
Mighty Therapeutics operates with its wholly owned subsidiary, Stealth BioTherapeutics. The company is building a proprietary pipeline intended to address bioenergetic deficits linked to mitochondrial dysfunction.
In September 2025, Mighty reached a major commercial milestone with U.S. Food and Drug Administration approval of its first commercial therapy. The company said that approval established the first FDA-approved treatment for Barth syndrome and the first FDA-approved therapy to directly target mitochondria.
Mighty continues to develop elamipretide in Barth syndrome, polymerase gamma-related mitochondrial disease, and dry age-related macular degeneration. The company is also progressing bevemipretide, its next-generation clinical candidate, for ophthalmic and neurological pathologies.
The company’s pipeline also includes preclinical assets SBT-255 and SBT-589 for rare mitochondrial disorders. Mighty said the new financing supports its broader leadership ambitions in mitochondrial medicine across multiple therapeutic areas.
KEY QUOTES:
“We are deeply gratified by Morningside’s ongoing support, and very excited to partner with K2 HealthVentures to accelerate and broaden our efforts to address the unmet medical needs of the many individuals living with diseases of mitochondrial dysfunction. These financings secure our access to the additional capital necessary to reach cash flow positivity, supporting our continued leadership of the burgeoning field of mitochondrial medicine across a broad range of therapeutic areas. With our strong commercial momentum and promising pipeline, we are poised for long-term growth and continued patient impact.”
Reenie McCarthy, CEO of Mighty Therapeutics
